White Paper

The Latest Trends In The Prevention And Treatment Of Cervical Cancer

Source: Mabion

Prepared By Adam Tuszyner, Registration Documentation Specialist, Pharmacovigilance Specialist

GettyImages-1294319145 breast cancer

Every year, cervical cancer is responsible for the death of hundreds of thousands of women, despite the wide availability of effective vaccinations and screening programs. Over the years, the industry has utilized immune checkpoint inhibitors, such as pembrolizumab, in the treatment of cervical cancer. These drugs have shown promise in restoring the body's natural anti-cancer immunity and improving survival rates for patients with advanced disease. Over time, other novel treatments has also been developed for cervical cancer, including adoptive T cell therapy, cancer vaccines, and CRISPR/Cas9-based therapies.

In addition to available treatment options and where research is headed, this article also covers the prevention of cervical cancer through HPV vaccination and regular screening. HPV vaccines have been shown to reduce the risk of developing cervical cancer by more than 50%, and screening tests can detect pre-cancerous lesions for early intervention. Despite these preventive measures, cervical cancer remains a significant global health issue, particularly in lower-income countries with limited access to screening and risk factors.

Explore the importance of increased awareness and participation in prevention programs to reduce the burden of cervical cancer and specifically, how novel biologic drugs are making a positive impact on patients' outcomes and well-being.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development